Approval · Notice of Compliance 28622 · 2022
ALUNBRIG: Notice of Compliance 28622
Issued July 20, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28622
- Date
- July 20, 2022
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Fulfilment of the Post-Approval Commitments for the Notice of Compliance with conditions
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ALUNBRIG | Not yet assigned | — |
Medicinal ingredients
- BRIGATINIB 30 MG per TAB
- BRIGATINIB 90 MG per TAB
- BRIGATINIB 180 MG per TAB